Not eradication. Absolute structural separation — the line this report draws between cultural heritage and clinical claims.
As a lifestyle philosophy, a dietary regimen, or a preventative ritual, traditional practices hold a recognized place in human culture.
But the moment an intervention claims to treat active pathology, execute invasive surgery, or alter human biochemistry, it must submit to the exact same rigorous, falsifiable standards as modern biomedicine.
Until that division is legally enforced, the placebo economy keeps thriving — saving state budgets while placing the physical toll on unprotected patients.
Drawing that line on paper is easy. Enforcing it takes an uncompromising policy framework — not a ban on tradition, but six structural reforms that separate cultural heritage from clinical validation.
Ch.3 already quantified the pipeline feeding this system: of the roughly 2.4 million students who sit India's medical entrance exam each year, the vast majority are filtered out by a fraction of a percentile or a multi-million-rupee capitation fee, and redirected into alternative-medicine degrees. Seen from the state's side of the ledger, that pipeline isn't a side effect of health policy — it's an academic unemployment pool, continuously refilled, that the system has no plan to drain.
Close the cross-practice loophole (Ch.2), void the surgical notifications (Ch.4), and end the evidentiary exemptions that let formulations skip clinical trials (Ch.1, Ch.5), and the parallel educational market mapped in Ch.3 collapses inside a single admissions cycle. That collapse hasn't happened, and won't happen without a fight, because the families funding BAMS and BHMS degrees aren't corporations — they're middle-class and rural households who sold land, liquidated savings, or took out education loans to buy a child's way into "the medical profession." If the state admits the resulting degree has no baseline clinical application, it instantly zeroes out an asset millions of families have already paid for.
Every co-location order and cross-practice exemption examined in Ch.2 does the same job twice: on paper, they preserve the resale value of a credential millions of families have already paid for — on the ground, at the expense of patient safety.
The capitation-fee economy mapped in Ch.3 isn't a cottage industry — the trusts running these colleges are frequently the same real-estate syndicates and political families who fund election campaigns. A regulatory change that strips a BAMS degree of its prescribing and surgical privileges doesn't just devalue a diploma; it collapses the customer base for an entire private college network built on upfront cash admissions. The state's reluctance to enforce its own evidentiary standards is, in no small part, downstream of who owns the buildings where those standards would have to be enforced.
The final reason is the most cynical, because it dresses up as competence. By routing NEET-rejected graduates into the rural clinics that residency-trained MDs refuse to staff (Ch.2), the state clears two reportable crises with a single contract: an otherwise-unemployed graduate becomes an "appointment," and a locked rural clinic becomes "functional" — both in the same press cycle, off the back of a salary that is a fraction of what an MD would cost. Unemployment statistics and universal-coverage statistics move in the right direction together, and the patient behind door three never appears in either spreadsheet.
None of this is a reason for resignation. It's the reason the reforms that follow cannot be advisory. A state that has spent decades building political, financial, and statistical dependencies on this pipeline will not retire it voluntarily — each payoff above has to be structurally removed, not just discouraged.
The first reform is the hardest, because it asks the state to give something up: co-location — the practice examined in Ch.2 of placing traditional practitioners inside modern clinics to pad staffing metrics on paper while the underlying vacancy goes unaddressed. Healthcare delivery has to run on two genuinely separate pathways, not one blended one.
Acute infection, metabolic crisis, or surgical need: the clinical track, full stop. No mixopathy crossover (Ch.4), no exceptions.
The "too holistic to test" defense — the systems-biology argument dismantled in Ch.5 — has to be retired. Even the WHO's own Global Traditional Medicine Strategy 2025–2034 frames the integration of traditional medicine into national health systems as conditional on strengthened evidence generation and regulatory safety, not as an exemption from either.
To stop private trusts from selling traditional degrees as a side door into modern medicine — the educational arbitrage mapped in Ch.3 — the credentials themselves need to stop misrepresenting what they are.
Ch.6 traced why corporate wellness brands win the narrative war: an overworked public physician has a few minutes per patient and defaults to a prescription pad, leaving the entire territory of diet, sleep, and behavior change open for a competitor to rebrand as ancient secret knowledge.
When a patient presents with early-stage metabolic disease or hypertension, the physician refers them to an in-house Lifestyle Medicine Wing — the same GLUT4 translocation and RAAS modulation Ch.6 already described, delivered by the system that understands the mechanism, instead of ceded to the system that profits from renaming it.
Ch.7 showed that the "Dr." prefix dispute is already settled in law: the NCAHP Act, 2021 establishes a Prefix Shield for registered allied and alternative practitioners, paired with a Suffix Mandate that legally requires their discipline to appear alongside it. The problem isn't the rule — it's that the rule was written for a nameplate, and enforcement stopped there.
Retiring the BAMS acronym (Reform 3) and enforcing the suffix at scale (Reform 5) are two sides of the same fix: a credential that accurately names what it is, displayed in a way that can't be cropped out of the frame.
The five reforms above are policy, not magic — each one needs a named office to sign it, fund it, or enforce it on the ground. Dismantling a crisis this deeply embedded means moving past general blame. Responsibility cannot be dumped onto a single individual: every actor inside the state apparatus has a highly specific, legally defined role in either maintaining the loophole or shutting it down.
What follows is that operational chain of command, from the local constituency to the top of the bureaucracy.
As the political head of the department, the Health Minister is the only office with the authority to draft cabinet notes, introduce legislation, and issue gazetted notifications — the absolute policy architect. Three signatures close most of the loophole on paper:
Below the political layer sits the administrative engine. The Health Secretary — a senior IAS officer — commands the state secretariat: the organ that frames administrative rules, allocates budgets, and controls public-health hiring contracts. The District Collector (DM) holds the same authority at district level.
Unlike the IAS, the Director General of Health Services (DGHS) and hospital superintendents are top-tier medical specialists — the clinical gatekeepers responsible for guidelines, drug quality control, and hospital security.
MPs and MLAs don't run hospitals or draft ministry rules. Their leverage is the budget vote and the floor question — the power to fund the offices above, or starve them.
The system survives on a game of circular blame: the politician points to the bureaucrat, the bureaucrat points to the budget, and the local representative points to the stars. Breaking the loop means locking three gears in sequence:
The Health Minister sets the policy line, the IAS Officer builds the funded pathway to execute it, and the DGHS enforces the scientific standard on the ground — the five reforms above only become real the moment all three gears turn together.
The solution is not to eliminate historical traditions, but to strip the marketplace of its profitable illusions. Clear regulatory boundaries are how the wealthy and the poor end up on the same standard of evidence-based care.
We solve the placebo economy not by waiting for the corporate cartel to regulate itself, but by making its business model completely obsolete.
Keep your kitchen stocked for minor homeostatic comfort. Keep your open-source database open for pure chemical transparency. And keep an allopathic emergency room on speed dial for acute biological crises. The era of profitable, uncritical blind compliance ends today.